US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of ...

Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...

Mind Medicine (MNMD) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

纽约 - 市值5.4852亿美元的临床阶段生物制药公司Mind Medicine (MindMed) Inc. (NASDAQ: MNMD)今日宣布,其用于治疗广泛性焦虑障碍 (GAD)的实验性药物MM120 ODT已获得英国药品和保健品监管局 (MHRA)颁发的创新通行证。根据InvestingPro的数据,该公司今年以来的股价表现出色,年初至今涨幅超过104%。这一认证是创新许可和准入途径 ...

FREE! Biopharma firm Mind Medicine announced that they have dosed the first-ever patient in a Phase 3 clinical trial of ...

Mind Medicine (MNMD) or MindMed announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically ...

For the first time ever, researchers are administering LSD to patients in a Phase 3 clinical trial. The new study focuses on whether the psychedelic can be used to effectively treat generalized ...

Charles Schwab Investment Management Inc. grew its holdings in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)的董事David W. Gryska最近购入了该公司2,500股普通股。这笔交易发生于2024年12月5日，每股价格为7.17美元，总投资额为17,925美元。这次购买的时机值得注意，因为根据InvestingPro的数据，该股票在过去一年里表现强劲，回报率高达114%。此次交易后，Gryska目前直接持有Mind ...

Check the time stamp on this data. Updated AI-Generated Signals for Mind Medicine (mindmed) Inc. (MNMD) available here: MNMD.

Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

“We are thrilled to welcome Gregg to the MindMed team. His leadership will strengthen our capabilities and accelerate our progress as we prepare to launch three Phase 3 studies of MM120 orally ...